Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) initiated the shares trading at $2.48 and showed positive change of +20.85% while the stock’s final trade was registered at $ 2.84. However, its previous closing price was seen at $2.35. The stock negotiated total number of 4.68 million shares as compared to 3 months average volume of 528.93 thousand shares.
The stock price demonstrated downbeat change from its 50 day moving average of 1.98 and had been up from its 200 Day Moving Average of 1.76.
Currently Idera Pharmaceuticals, Inc. (IDRA) captured an average recommendation of “ Buy ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “3″ Analysts”. “0” rated “Sell” for the company. “0” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $5.00 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $6.00 however minimum price target advised by analysts is $4.00. The Median price target for the stock is measured at $5.00.
Presently, Analysts decided consensus EPS estimate of $-0.11 for present quarter and one month ago projected EPS estimate was at $-0.11. If we take a look at back 3 month ago, consensus EPS estimate was $-0.12.
A current consensus EPS estimate for next quarter is at $-0.11 and 3 month ago EPS forecast was $-0.11. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.11.
For current fiscal year, most recent EPS estimate is set at $-0.45 based on Analyst consensus and three month ago consensus EPS opinions was at $-0.44. During period one month ago, consensus EPS forecast was decided at $-0.45.
A current consensus EPS projection for next fiscal year is observed at $-0.46 and one month ago consensus EPS forecast was at $-0.46. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.46 by analysts.
One Month ago, the stock has gained consensus mean rating of Buy based on the analysis of brokerage analyst firms polled. 3 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 0 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 4 said a “Buy Rating” and 0 announced “Overweight Rating”. 0 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.